ThomasNet Home   |   Promote Your Business
Home  |   My ThomasNet News®  |   Industry Market Trends  |   Submit Release  |   Advertise  |   About Us Feb 14, 2012  

Xoft to Present at the 26th Annual JPMorgan Healthcare Conference

Print | 
Email |  Comment   Share  

(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)

Xoft, Inc.
49000 Milmont Drive,
Freemont, CA, 94538
USA



Press release date: January 3, 2008

CEO to Provide Update on the Clinical and Commercial Adoption of the Axxent® Electronic Brachytherapy System

FREMONT, Calif., Jan. 3 -- Xoft, Inc., developer of the Axxent® Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 26th Annual JPMorgan Healthcare Conference. Xoft president and CEO Michael Klein will present on Thursday, January 10, 2008, at 7:30am PST at The Westin St. Francis Hotel in San Francisco.

"We are excited to have the opportunity to provide an update on the adoption of this exciting new method of delivering internal radiation therapy since we went fully commercial in Q4 of 2007," said Klein. "With breast cancer, the first FDA cleared indication for the Axxent System, we are already seeing excellent clinical results at the 10 initial clinical sites and more than a dozen commercial sites that have committed since we went commercial. Combined with strong awareness among the oncology community and the recent establishment of Medicare payment for Electronic Brachytherapy in the outpatient hospital setting, we expect rapid and widespread commercial adoption, making it available to women who want to take advantage of breast conserving therapy."

Cleared by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, the Axxent System is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings.

Use of the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the time required for radiation therapy for early stage breast cancer from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy. Effective July 2007, the CPT code for electronic brachytherapy is included in the AMA CPT 2008 codebook. Additionally, the Category III CPT Code 0182T: high dose rate electronic brachytherapy, per fraction, has been assigned a New Technology Ambulatory Payment Classification (APC). The APC payment applies to the outpatient hospital and ambulatory surgical center settings and includes the high dose rate electronic brachytherapy radiation treatment and the cost of the X-ray source.

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent® Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Source: Xoft, Inc.

CONTACT: Chris K. Joseph, +1-510-339-2293, chris@ckjcomm.com, for Xoft, Inc.
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



 Newsletters
Industry Market Trends
Has Got It
  • Latest developments
  • Trends
  • Best practices
  • Opinions & Commentary
Get Ahead. Get IMT.
Subscribe Free Today
Subscribe   View Sample

Your Gateway to a Fast Changing World
Product News Alerts
Receive similar stories and other customized news to keep you in the know on the products shaping industry.
Subscribe Free Today
Subscribe   View Sample
 Other News from this company:
Xoft Reaches Milestone as Axxent® Electronic Brachytherapy System Is Used to Treat Early Stage Breast Cancer Patients
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-Mail Story
Save Story


Home  |  My ThomasNet News®  |  Industry Market Trends  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2012 Thomas Publishing Company
Terms of Use - Privacy Policy